A randomised study of intravenous bolus versus continuous infusion of ifosfamide and doxorubicin with oral etoposide for small-cell lung cancer

H. Anderson; J. Prendiville; N. Thatcher; J. A. Radford; R. Swindell

doi:10.1007/BF01613219

A randomised study of intravenous bolus versus continuous infusion of ifosfamide and doxorubicin with oral etoposide for small-cell lung cancer

H. Anderson, J. Prendiville, N. Thatcher, J. A. Radford, R. Swindell

Research output: Contribution to journal › Article › peer-review

Abstract

159 "poor risk" patients with previously untreated small cell lung cancer were entered into a randomised study of intravenous bolus versus continuous infusion chemotherapy with doxorubicin on weeks 1,3,5 and ifosfamide with mesna on weeks 2, 4, 6. Oral etoposide was given on days 1-5, 15-19, and 29-33. There was no difference in response rate or survival. However, patients treated with continuous infusion therapy had significantly less haematological toxicity (P=0.0007), and less nausea and vomiting (P=0.03). © 1991 Springer-Verlag.

Original language	English
Pages (from-to)	S139-S140
Journal	Journal of Cancer Research and Clinical Oncology
Volume	117
Issue number	4
DOIs	https://doi.org/10.1007/BF01613219
Publication status	Published - Jul 1991

Keywords

Bolus
Continuous infusion
Oral etoposide
Small-cell lung cancer

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/BF01613219

Cite this

@article{f488dbf59fe8445c92d228983a19c558,

title = "A randomised study of intravenous bolus versus continuous infusion of ifosfamide and doxorubicin with oral etoposide for small-cell lung cancer",

abstract = "159 {"}poor risk{"} patients with previously untreated small cell lung cancer were entered into a randomised study of intravenous bolus versus continuous infusion chemotherapy with doxorubicin on weeks 1,3,5 and ifosfamide with mesna on weeks 2, 4, 6. Oral etoposide was given on days 1-5, 15-19, and 29-33. There was no difference in response rate or survival. However, patients treated with continuous infusion therapy had significantly less haematological toxicity (P=0.0007), and less nausea and vomiting (P=0.03). {\textcopyright} 1991 Springer-Verlag.",

keywords = "Bolus, Continuous infusion, Oral etoposide, Small-cell lung cancer",

author = "H. Anderson and J. Prendiville and N. Thatcher and Radford, {J. A.} and R. Swindell",

year = "1991",

month = jul,

doi = "10.1007/BF01613219",

language = "English",

volume = "117",

pages = "S139--S140",

journal = "Journal of Cancer Research and Clinical Oncology",

issn = "0171-5216",

publisher = "Springer Nature",

number = "4",

}

TY - JOUR

T1 - A randomised study of intravenous bolus versus continuous infusion of ifosfamide and doxorubicin with oral etoposide for small-cell lung cancer

AU - Anderson, H.

AU - Prendiville, J.

AU - Thatcher, N.

AU - Radford, J. A.

AU - Swindell, R.

PY - 1991/7

Y1 - 1991/7

N2 - 159 "poor risk" patients with previously untreated small cell lung cancer were entered into a randomised study of intravenous bolus versus continuous infusion chemotherapy with doxorubicin on weeks 1,3,5 and ifosfamide with mesna on weeks 2, 4, 6. Oral etoposide was given on days 1-5, 15-19, and 29-33. There was no difference in response rate or survival. However, patients treated with continuous infusion therapy had significantly less haematological toxicity (P=0.0007), and less nausea and vomiting (P=0.03). © 1991 Springer-Verlag.

AB - 159 "poor risk" patients with previously untreated small cell lung cancer were entered into a randomised study of intravenous bolus versus continuous infusion chemotherapy with doxorubicin on weeks 1,3,5 and ifosfamide with mesna on weeks 2, 4, 6. Oral etoposide was given on days 1-5, 15-19, and 29-33. There was no difference in response rate or survival. However, patients treated with continuous infusion therapy had significantly less haematological toxicity (P=0.0007), and less nausea and vomiting (P=0.03). © 1991 Springer-Verlag.

KW - Bolus

KW - Continuous infusion

KW - Oral etoposide

KW - Small-cell lung cancer

U2 - 10.1007/BF01613219

DO - 10.1007/BF01613219

M3 - Article

C2 - 1665490

SN - 0171-5216

VL - 117

SP - S139-S140

JO - Journal of Cancer Research and Clinical Oncology

JF - Journal of Cancer Research and Clinical Oncology

IS - 4

ER -

A randomised study of intravenous bolus versus continuous infusion of ifosfamide and doxorubicin with oral etoposide for small-cell lung cancer

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this